Per Med. Author manuscript; available in PMC 2014 May 01.

Published in final edited form as:

Per Med. 2013 May 01; 10(3): 213–216. doi:10.2217/PME.13.10.

All the post-genomic world is a stage: the actors and narrators required for translating pharmacogenomics into public health

Edward S. Dove^{1,2,*} and Vural Özdemir^{1,3,*}

¹Centre of Genomics and Policy, Department of Human Genetics, Faculty of Medicine, McGill University, Montreal, QC, Canada

²Columbia Law School – LL.M. Program, New York, NY, USA

³Data-Enabled Life Sciences Alliance International (DELSA Global), Seattle, WA, USA

Keywords

Genomics and development; genomics without borders; global governance of biotechnology innovation and uncertainty; LGBT community; LMICs; public health pharmacogenomics; reflexive technology governance; responsible innovation; science and technology studies; taxonomy of knowledge-based innovation

“A taxonomy of actors and dual-order narrators takes the concept of innovation systems to a new level of stringency and standards.”

TAKING INNOVATION FROM THE CLINIC TO THE STREETS

The now decade-old post-genomic era is marked with stories of triumph and tribulation, hope and hype, and gradual, sometimes serendipitous, innovations in personalized medicine [1]. While governments have prioritized research and development (R&D) and moving discoveries from laboratory to innovation [2], innovations (especially those in the biotechnology sector) have often underwhelmed governments, investors and the public in terms of utility [3]. As the post-genomics era moves into its second decade, including direct-to-consumer genomics [4], we suggest that the personalized medicine innovation system is highly fluid and in flux as a result of disappointment and fiscal restraint, and old orders of understanding innovation's nature and function are undergoing transformation. Much of the western world is now locked in a straightjacket of budgetary constriction; past calls for more R&D funding simply will not do as the fight for increasingly small resources intensifies and citizens resist the idea of greater taxation. New ways of conceptualizing innovation must

Correspondence: Vural Özdemir, MD, PhD, DABCP, Associate Professor, Faculty of Medicine, McGill University, yural.ozdemir@alumni.utoronto.ca.

*Both authors contributed equally to this article.

COMPETING INTERESTS DISCLOSURE

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

take hold, embracing uncertain, contingent, discursive processes and questioning prior unchecked assumptions, values and constraints in the innovation system.

We propose a new taxonomy for the “public health pharmacogenomics” innovation ecosystem [5,6], labeled “actors” and “narrators”, which takes innovation out of the lab and into the “streets”, while examining the embedded interests and unchecked power structures impacting knowledge co-production among the innovation actors.

ACTORS AND NARRATORS: A NEW TAXONOMY FOR INNOVATION ECOSYSTEMS

Innovations are now being understood, given their financial and societal significance, as engaged practices that move discursively in a knowledge ecosystem. While we certainly support the extant move towards “opening up” the discussion on scientific design [7], there is a danger in succumbing to a false sense of assuredness that simply by bringing more people to the table, the innovation system will magically be more ethically just and socially robust. We cannot merely wish it so.

To avoid falling into the trap of tokenism or unidirectional political legitimacy (i.e., more is always better), research funding agencies invested in pharmacogenomics and traditional innovation actors such as academic scientists, industry, and governments must remain cognizant that aggregating publics and creating more time and space for dialogue do not necessarily lead to innovation or to better innovation that is sustainable [8]. Multitudes of voices and opinions, brought together without a sound social theory, can be cacophonous, counter-productive and at risk for tokenism [9].

One of us (V. Özdemir) has outlined a new taxonomy for understanding innovations and the attendant knowledge ecosystems as consisting of “actors” and “narrators” [10]. In this taxonomy, innovation actors – those who carry out core discovery and translational work – like pharmacogenomics scientists, are situated at arm’s length from first-order narrators, such as social scientists, lawyers, philosophers and bioethicists, who, armed with their own variable form of expertise, are acknowledged to play a critical role in exploring the ethical, legal and social implications of post-genomics research for individuals, families and communities. But, as with innovation actors, first-order narrators never come free of social interests or implications. In our proposed nested governance frame for knowledge-based innovations [10], first-order narrators are subject to engagement by experienced-based second-order narrators such as citizen scholars, knowledge end-users and traditionally marginalized groups, so as to prevent actors and first-order narrators from gaining excessive power that can be misused in the course of steering innovations. The dual ordering of narrators as distinct from actors is crucial for the additional reasons we explain below.

LISTENING TO THE SOUND OF SILENCE: TOWARDS A SOCIOLOGY OF BIOETHICS

We have long seen the emergence of different professionals, such as social scientists, bioethicists and philosophers, engaged in a narrator role in pharmacogenomics, but our

taxonomy of knowledge co-production noted above takes the actor-narrator dialectic to a greater level of accountability by underscoring that first-order narrators also have self-interests that ought to be made explicit for innovations to be transparent, sustainable and trustworthy by its constituents. For example, the well-known careerism that is endemic in academia, industry, governments and the 21st century workplace, or personal career interests of individuals, can taint the narrators' account of the innovation actors. Just as scientists are not immune to partisanship [11], innovation narrators are also rooted in partisan fray, although latent it often may be. Yet narrators have so far not been subjected to this higher level of accountability, despite the trailblazing work of some "bioethics observers" like Raymond De Vries, Renee Fox and Judith Swazey, who have in essence advocated for an "ethics of bioethics" or "sociology of bioethics" so as to unpack and explicate these tensions embedded in an unchecked narrator role [12,13].

We propose the concept of a second-order narrator precisely to address this accountability gap among the classic first-order narrators, while recognizing and endorsing their importance in the post-genomics innovation knowledge ecosystem. Moreover, we suggest that for innovations to be integrated "socio-technically" and embedded in societal values and therefore robust, as advocated by leading genomics R&D funding agencies such as the Wellcome Trust, Genome Canada and the National Institutes of Health (NIH), we need such nested and self-calibrating governance systems to respond to uncertainties of biotechnology and post-genomics knowledge.

The taxonomy of innovations as actors and nested narrator systems is also important for being truly inclusive in a manner informed by inherent power differences among the constituents of an innovation ecosystem. In effect, our proposed taxonomy guides decisions as to how we select different innovation actors in an engagement practice for innovations, and how we define inclusivity beyond the false face value of simply including some "player" in a staging role. Much of the extant personalized medicine engagement exercises have been narrowly framed and did not include the second-order narrators. In accordance with this, Raymond De Vries has aptly noted:

Sociology and bioethics have an uneasy relationship. Bioethicists find sociology helpful for describing and analyzing ethical issues, but they are less enthusiastic when bioethics becomes the subject of sociological scrutiny [13].

This observation also underscores that the role of a second-order innovation narrator is not one of popularity contest, and subject to potential professional marginalization although it is essential for credibility and long-term sustainability of personalized medicine innovations.

A taxonomy of actors and dual ordered narrators takes the concept of innovation systems to a new level of stringency and standards. It is not a matter of simply thinking who is included or not, but instead thinking about the hitherto unchecked power systems and self-interests at play, and their consequential and collateral effects, on the post-genomics stage. These self-interests are neither necessarily malignant nor benevolent; interests and inescapable politics embedded in science and technology practice and in due course, innovations, do exist [14]. Ultimately, the uptake of pharmacogenomics might be improved if both scientific and bioethics (and attendant social science, philosophy and law) institutions expressed an

equivalent reflexive discourse, i.e., being cognizant of how our own values and silent value-commitments impact the conclusions we reach (e.g., ethical/unethical technology, person, company, etc.).

TAKING INNOVATIONS TO THE CITIZENS OF LOW- AND MIDDLE-INCOME COUNTRIES

This interconnectedness matters, for there is another neglected but important role that both sets of the innovation constituents play: actors and narrators not only have self-interests, but may be reluctant to come out and engage or participate in the innovation ecosystems because doing so may risk their wellbeing, safety or careers. Consider, for example, the case of hypersensitivity reaction to abacavir, a nucleoside reverse transcriptase inhibitor (NRTI) drug used in persons with Human Immunodeficiency Virus (HIV) infection. This serious hypersensitivity occurring in up to 9% of persons receiving abacavir has a strong genetic component associated with the major histocompatibility complex (MHC) allele, *HLA-B*5701*. The genetic testing for this variant is now recommended in clinical guidelines and is practiced in most Western countries [15]. However, advocating for availability or distribution of, or seeking, HIV therapy in many low- and middle-income countries (LMICs), let alone abacavir genetic testing for its personalized use, may trigger severe, irreversible social consequences. At the extreme but not uncommon end, it can lead to the disclosure of the HIV status of an individual. Stigma, ostracization and discrimination can result, with assumptions that an advocate is wrongfully aligned with an infected person who has allegedly a “sinful” lifestyle, be it as a drug user, sex worker or lesbian-gay-bisexual-transgendered (LGBT) person, not recognizing (at the very least) that HIV is an epidemic that affects all of society.

Moreover, while citizens may turn to legal protection to combat these potentially negative reactions, there is a vast disconnect between “the law on the streets” and “the law in the books”; people who risk marginalization may find that turning to the law for support is limited or can even be futile in some LMICs [16]. Seen in this light, all the stage players cannot readily come together to build scientific knowledge. Narrators can serve the role of interactional expert advocates for marginalized innovation actors.

MOVING OUTSIDE OUR PHARMACOGENOMICS ECHO CHAMBER FOR SUSTAINABLE INNOVATION

In the envisioned post-genomic worlds, upon which a stage of narrators and actors perform innovative practices and deliver innovative technologies, we strongly advocate for the need to think outside our self- or socially assigned actor or narrator roles. Removing systemic obstacles to the health and wellbeing of all involves engagement in an innovation ecosystem that is truly inclusive both on paper and the streets, when technologies such as pharmacogenomics are being used for abacavir testing in LMICs for LGBTs and other marginalized groups.

Sadly, we still live in a world riddled with racism, sexism, xenophobia, anti-Semitism, bullying and homophobia. Moreover, “extreme neutrality”, i.e., conscious indifference stemming from a self-serving desire to remain popular with those in power, is another endemic ill in our global society, be it in LMICs and non-LMICs.

We in the field of public policy, science and technology studies (STS), law, pharmacogenomics, public health and personalized medicine can do our part, starting with including LMIC LGBT persons as a legitimate part of the discourse in technologies that can affect them, as well as other marginalized groups such as women in LMICs who may benefit from certain genetic tests for drug therapy.

Equally important, engagement or advocacy on behalf of the disadvantaged groups should be carried out both by self-identifying members of these groups, but also by outsiders to marginalized communities who believe in social justice as a principle [10, 16, 17].

In the current era, when pharmacogenomics applications are often advancing to public health practice and from developed countries to LMICs, it is noteworthy that truly groundbreaking work is more likely to appear from marginal, dissident, or unexpected sources, rather than from the well-established and entrenched powerful mainstream.

While this is well recognized within the arts community (consider, for example, the innovative graffiti art and the chalk figures drawn by Keith Haring on New York City subway posters in the 1980s outside the exclusivist gallery and museum system [101]), the emergence of new unprecedented forms of public health pharmacogenomics knowledge will demand a keen knowledge of both global and local (GloCal) knowledge [18]. Only through such a nuanced and integrated approach can a nested and freely engaged multi-layer innovation ecosystem be designed and sustained, including in LMICs.

In the face of the deep fault lines that fracture 21st century human civilization and communities, which stand on an increasingly unsustainable and precarious pedestal, understanding the nature of innovation actors and first- and second-order narrators will pave the way not only for pharmacogenomics action on the streets, but also an open society [201] where publics can assume the role of actors as citizen scientists, as well as narrators of the first and second kind. Such hybridity is to be cherished, for it is intrinsically good and a *conditio sine qua non* for a socially robust and sustainable post-genomics personalized medicine.

Acknowledgments

The analysis, concepts and work reported herein were informed and supported by the following research grants to the authors: V. Özdemir (Canadian Institutes of Health Research, CIHR, operating research grant, #84620, on pharmacogenomics policy, and a research grant from the Social Sciences and Humanities Research Council, 231644, on emerging biotechnology foresight research).

The idea of actors and dual-order narrators was proposed by V. Özdemir in a former paper [10], wherein the concept of wiki-governance [19] was proposed by E.S. Dove to operate such nested innovation knowledge ecosystems. Both E.S. Dove and V. Özdemir are second-order narrators of post-genomics biotechnology and knowledge-based innovation. V. Özdemir is a pharmacogenomics scientist and medical doctor by training.

The views and analysis reported herein are entirely the authors' personal opinions and do not represent the views of the affiliated institutions nor the funding agencies.

We thank the Personalized Medicine Commissioning Editor Sarah Miller for peer-review and comments to amend and revise the article in its present form.

ABBREVIATIONS

HIV	Human Immunodeficiency Virus
LGBT	Lesbian, gay, bisexual and transgendered people
LMIC	Low- and middle-income country
NIH	National Institutes of Health
NRTI	Nucleoside reverse transcriptase inhibitor
R&D	Research and development
STS	Science and technology studies

References

1. Tutton R. Personalizing medicine: futures present and past. *Soc Sci Med.* 2012; 75(10):1721–1728. [PubMed: 22906526]
2. Özdemir V, Muljono DH, Pang T, et al. Asia-Pacific Health 2020 and Genomics without Borders: co-production of knowledge by science and society partnership for global personalized medicine. *Curr Pharmacogenomics Person Med.* 2011; 9(1):1–5. [PubMed: 21490881]
3. Nuffield Council on Bioethics. Emerging biotechnologies: technology, choice and the public good. Nuffield Council on Bioethics; London, UK: 2012.
4. Vayena E, Gourni E, Streuli J, et al. Experiences of early users of direct-to-consumer genomics in Switzerland: an exploratory study. *Public Health Genomics.* 2012; 15(6):352–362. [PubMed: 23154382]
5. Özdemir V, Fisher E, Dove ES, et al. End of the beginning and public health pharmacogenomics: knowledge in 'Mode 2' and P5 medicine. *Curr Pharmacogenomics Person Med.* 2012; 10(1):1–6. [PubMed: 22545073]
6. Özdemir V, Borda-Rodriguez A, Dove ES, et al. Public health pharmacogenomics and the design principles for global public goods – moving genomics to responsible innovation. *Curr Pharmacogenomics Person Med.* in press.
7. Stirling A. 'Opening up' and 'closing down': power, participation, and pluralism in the social appraisal of technology. *Sci Technol Human Values.* 2008; 33(2):262–294.
8. Wynne B. Misunderstood misunderstanding: social identities and public uptake of science. *Public Underst Sci.* 1992; 1(3):281–304.
9. Wynne B. Public engagement as a means of restoring public trust in science--hitting the notes, but missing the music? *Community Genet.* 2006; 9(3):211–220. [PubMed: 16741352]
10. Dove ES, Faraj SA, Kolker E, Özdemir V. Designing a post-genomics knowledge ecosystem to translate pharmacogenomics into public health action. *Genome Med.* 2012; 4:91. [PubMed: 23194449]
11. Guston DH, Sarewitz D, Miller C. Scientists not immune to partisanship. *Science.* 2009; 323:582.
12. Fox, RC., Swazey, JP. *Observing Bioethics.* Oxford University Press; Oxford, UK: 2008.
13. De Vries R. How can we help? From 'sociology in' to 'sociology of' bioethics. *J Law Med Ethics.* 2004; 32(2):279–292. [PubMed: 15301193]
14. Dove ES, Özdemir V. 'Regular science' is inherently political. *EMBO Rep.* 14(2):113.

15. Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. *Br J Clin Pharmacol*. 2011; 71(5):659–671. [PubMed: 21480946]
16. Özdemir V. What to do when the risk environment is rapidly shifting and heterogeneous? Anticipatory governance and real-time assessment of social risks in multiply marginalized populations can prevent IRB mission creep, ethical inflation or underestimation of risks. *Am J Bioeth*. 2009; 9(11):65–68.
17. Epstein, S. *Impure Science: AIDS, Activism, and the Politics of Knowledge*. University of California Press; Berkeley, USA: 1996.
18. Özdemir V. OMICS 2.0: a practice turn for 21(st) century science and society. *OMICS*. 2013; 17(1):1–4. [PubMed: 23301640]
19. Dove ES, Joly Y, Knoppers BM. Power to the people: a wiki-governance model for biobanks. *Genome Biol*. 2012; 13:158. [PubMed: 22647613]

MULTIMEDIA

101. Aubert, E. *Drawing the line [videorecording]: a portrait of Keith Haring*. Biografilm Associates; West Long Branch, USA: 1989.

WEBSITES

201. Havel, Vaclav. Address by Czech Republic President Vaclav Havel in acceptance of “Open Society”. Prize by the Central European University; Budapest, Hungary: Jun 24. 1999 http://old.hrad.cz/president/Havel/speeches/1999/2406_uk.html [Accessed 30 January 2013]